Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.

Publication date: Jul 07, 2019

Objective: To assess masitinib in the treatment of ALS. Methods: Double-blind study, randomly assigning 394 patients (1:1:1) to receive riluzole (100 mg/d) plus placebo or masitinib at 4.5 or 3.0 mg/kg/d. Following a blinded transition from phase 2 to phase 2/3, a prospectively defined two-tiered design was implemented based on ALSFRS-R progression rate from disease-onset to baseline (ΔFS). This approach selects a more homogeneous primary efficacy population (“Normal Progressors”, ΔFS

Mora, J.S., Genge, A., Chio, A., Estol, C.J., Chaverri, D., Hern’andez, M., Mar’In, S., Mascias, J., Rodriguez, G.E., Povedano, M., Paipa, A., Dominguez, R., Gamez, J., Salvado, M., Lunetta, C., Ballario, C., Riva, N., Mandrioli, J., Moussy, A., Kinet, J.P., Auclair, C., Dubreuil, P., , Arnold, Mansfield, C.D., Hermine, O., and GROUP, AB10015 STUDY. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. 18548. 2019 Amyotroph Lateral Scler Frontotemporal Degener.

Concepts Keywords
ALS Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis Drugs
Causality Health
Cohort Neurological disorders
Conservative RTT
Double Blind Clinical research
Homogeneous Masitinib
Missing Antidepressants
Placebo Amyotrophic lateral sclerosis
Randomized Clinical Trial Riluzole
Robustness Placebo
Clinical trial
Sertraline

Semantics

Type Source Name
gene UNIPROT SLC35G1
gene UNIPROT TLE5
gene UNIPROT FASTK
disease MESH multiple
gene UNIPROT SOD1
gene UNIPROT IGFALS
disease DOID amyotrophic lateral sclerosis
disease MESH amyotrophic lateral sclerosis
drug DRUGBANK Riluzole
drug DRUGBANK Masitinib

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *